Novartis, Pfizer and Hengrui all have more than 10 products competing for the 2022 medical insurance directory

【Pharmaceutical Network Industry News】 On the evening of September 6, the State Medical Insurance Bureau issued the "Announcement on Publicizing the Drugs and Related Information Of the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue Adjustment in 2022" through preliminary review, and a total of 344 varieties passed the preliminary examination
.

Through combing, it was found that 9 companies declared more than 5 drugs this year, while Novartis, Pfizer and Hengrui Pharmaceutical had more than 10 products to compete! Among them, Novartis has 14 products participating in this year's health insurance negotiations
.

Among Novartis' 14 drugs, except for offaldomizumab injection, the remaining drugs have previously been included in the medical insurance list
through medical insurance negotiations.

It is reported that Novartis targeted CD20 bispecific antibody omalumizumab injection, which was approved for marketing in China in December 2021 for adult recurrent multiple sclerosis (RMS), including clinical isolated syndrome, relapse-remitting multiple sclerosis and active secondary progressive multiple sclerosis
.

Industry insiders also said that Novartis' preliminary list of edlopapazolamine tablets, everolimus tablets and omalizumab for injection are also products
that have attracted much attention.

Taking edupopipalaethanolamine tablets as an example, in December 2017, the product was approved to enter China, and in 2019, the product reached more than 69 million yuan in domestic sales, and successfully entered the national medical insurance class B range, and successfully renewed in 2020
.

In addition, Novartis Class 1 innovative drug Sinimod tablets also appeared on this year's preliminary review list
of medical insurance negotiations.

It is reported that the product was approved for listing in 2020 through the priority review and approval procedure, and successfully entered the medical insurance directory in the medical insurance negotiations of that year for the treatment of adult recurrent multiple sclerosis
.

Pfizer has 11 products participating in this year's health insurance negotiations
.

Among them, piperelli capsules, digarek acetate for injection, etc.
entered the preliminary list, and these products also appeared on the preliminary list
last year.

According to the data, Pfizer's piperacilly capsules were approved for listing by the US FDA in February 2015, and the global sales revenue in 2021 reached 5.
437 billion US dollars; it was approved for listing in China in 2018 and has not yet entered the national medical insurance directory
.

According to data from the intranet, in 2021, the sales of Pipersili terminals of China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) exceeded 100 million yuan, an increase of 89.
50%
year-on-year.

In this year's medical insurance talks, Hengrui Pharmaceutical also participated with 10 products
.

These include proline henpagliflozin tablets, dalcilly isethionate tablets, reviruter tablets, pirroltinib maleate tablets and remazolam toluene sulfonate for injection 5 domestic original research drugs
.

Data show that proline hepagliflozin is a sodium-glucose synergistic transporter 2 (SGLT2) inhibitor that reduces the reabsorption of tubular filtered glucose by inhibiting SGLT2, thereby increasing urinary glucose excretion
.

Proline hepagliflozin is a class 1 new drug approved by Hengrui Pharmaceutical at the end of 2021, and it is also a domestic innovative SGLT-2 inhibitor
.

In addition, Reverrustamine is a new AR inhibitor with independent intellectual property rights developed by Hengrui Pharmaceutical, and a new AR inhibitor
independently developed by China.

As a new AR inhibitor, reverrustamine has made important innovations in the molecular structure of the drug, so that the drug has a high activity of AR inhibition, the blood-brain barrier permeability is significantly reduced compared with similar products on the market, and the central nervous system toxicity is reduced, and it has more optimized pharmacokinetic characteristics
.

In addition to the above enterprises, the number of drugs declared by Sanofi (Beijing), AstraZeneca (Wuxi) and Chia Tai Tianqing is 7; Bayer declared 6 drugs; Jiangsu Haosen and BeiGene (Beijing) declared 5 drugs
.

Disclaimer: In no event shall the information or opinions expressed herein constitute investment advice
to any person.